カテゴリ： GlobalData, オランダ, 企業調査

UniQure NV (QURE)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：UniQure NV (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9965
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：88
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：オランダ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
UniQure NV (UniQure) develops and markets gene therapy products. The company develops adeno-associated virus based gene therapies using its gene technology platform. UniQure offers clinical and preclinical programs for lipoprotein lipase deficiency, hemophilia A and B, Huntington’s disease, congestive heart failure and other research targets. The company develops a gene platform to bring new disease modifying therapies to patients with genetic diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions. UniQure is headquartered in Amsterdam, the Netherlands.

UniQure NV (QURE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
UniQure NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
UniQure NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
UniQure NV, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
UniQure Acquires Patents from University of Padova 12
Venture Financing 13
uniQure Raises Additional USD10 Million in Venture Debt Financing 13
uniQure Raises US$10 Million In Venture Financing 14
UniQure Raises USD17.5 Million in Venture Financing 15
Partnerships 16
Bristol-Myers Squibb Enters into Agreement with uniQure 16
Synpromics Extends Co-Development Agreement with uniQure for Gene Therapy Vector 17
uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 18
Licensing Agreements 19
uniQure Enters into Licensing Agreement with 4D Molecular Therapeutics 19
uniQure Enters into Licensing Agreement with Protein Sciences 20
uniQure Enters into Licensing Agreement with Cold Spring Harbor Laboratory 21
Treeway Enters into Licensing Agreement with uniQure 22
Benitec Biopharma Enters Into Licenising Agreement With uniQure 23
uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 24
Equity Offering 25
uniQure Raises USD147.5 Million in Public Offering of Shares 25
uniQure Raises USD91.2 Million in Public Offering of Shares 27
uniQure Raises USD38 Million in Private Placement of Shares 29
uniQure Raises USD88.5 Million in Public Offering of Shares 30
uniQure Completes IPO For US$91.8 Million 32
InoCard Spin Out from University of Heidelberg 34
uniQure Announces Private Placement Of Shares For US$7.8 Million 35
Acquisition 36
UniQure Acquires InoCard for USD5.7 Million 36
uniQure Acquires Amsterdam Molecular Therapeutics, Developer Of Gene Therapy 37
UniQure NV – Key Competitors 39
UniQure NV – Key Employees 40
UniQure NV – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Nov 06, 2018: uniQure announces third quarter 2018 financial results and highlights company progress 42
Aug 08, 2018: uniQure announces second quarter 2018 financial results and highlights company progress 44
Apr 30, 2018: uniQure Reports First Quarter 2018 Financial Results 47
Mar 14, 2018: uniQure Announces 2017 Financial Results and Recent Company Progress 49
Nov 01, 2017: uniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress 51
Aug 08, 2017: uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress 54
May 09, 2017: uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress 56
Mar 15, 2017: uniQure Announces 2016 Financial Results and Provides Update on Company Progress 58
Jan 25, 2017: uniQure Appoints Alexander Kuta as Senior Vice President of Regulatory Affairs 60
Corporate Communications 61
Jun 13, 2018: uniQure Announces New Appointments to its Board of Directors 61
Dec 11, 2017: uniQure Added to NASDAQ Biotechnology Index 62
Aug 07, 2017: uniQure Announces Leadership Team Appointments and Nominations to its Board of Directors 63
Jun 06, 2017: uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer 65
Product News 66
12/09/2017: uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting 66
11/01/2017: uniQure Announces Presentations at the 59th American Society of Hematology Annual Meeting 67
07/21/2017: uniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program 69
07/11/2017: uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene Therapy in the Presence of Pre-Existing Neutralizing Antibodies 70
07/10/2017: uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B 71
06/23/2017: uniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis Congress 73
Jun 15, 2017: uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies 74
May 11, 2017: uniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates 75
04/24/2017: uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy 76
04/04/2017: uniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System 77
02/06/2017: uniQure Announces Presentations at Upcoming February Conferences 78
Product Approvals 79
Apr 25, 2017: uniQure Receives European Medicines Agency Priority Medicines Designation for AMT-060 in Hemophilia B 79
Jan 30, 2017: uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B 80
Clinical Trials 81
Oct 19, 2017: uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018 81
May 10, 2017: uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates 83
Apr 26, 2017: uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at CHDI’s 12th Annual Huntington’s Disease Therapeutics Conference 84
Other Significant Developments 85
Jan 08, 2018: uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value 85
Jan 09, 2017: uniQure Outlines Key Initiatives for 2017 and Vision for 2018 87
Appendix 88
Methodology 88
About GlobalData 88
Contact Us 88
Disclaimer 88

List of Tables
UniQure NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
UniQure NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
UniQure NV, Deals By Therapy Area, 2012 to YTD 2018 9
UniQure NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
UniQure Acquires Patents from University of Padova 12
uniQure Raises Additional USD10 Million in Venture Debt Financing 13
uniQure Raises US$10 Million In Venture Financing 14
UniQure Raises USD17.5 Million in Venture Financing 15
Bristol-Myers Squibb Enters into Agreement with uniQure 16
Synpromics Extends Co-Development Agreement with uniQure for Gene Therapy Vector 17
uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 18
uniQure Enters into Licensing Agreement with 4D Molecular Therapeutics 19
uniQure Enters into Licensing Agreement with Protein Sciences 20
uniQure Enters into Licensing Agreement with Cold Spring Harbor Laboratory 21
Treeway Enters into Licensing Agreement with uniQure 22
Benitec Biopharma Enters Into Licenising Agreement With uniQure 23
uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 24
uniQure Raises USD147.5 Million in Public Offering of Shares 25
uniQure Raises USD91.2 Million in Public Offering of Shares 27
uniQure Raises USD38 Million in Private Placement of Shares 29
uniQure Raises USD88.5 Million in Public Offering of Shares 30
uniQure Completes IPO For US$91.8 Million 32
InoCard Spin Out from University of Heidelberg 34
uniQure Announces Private Placement Of Shares For US$7.8 Million 35
UniQure Acquires InoCard for USD5.7 Million 36
uniQure Acquires Amsterdam Molecular Therapeutics, Developer Of Gene Therapy 37
UniQure NV, Key Competitors 39
UniQure NV, Key Employees 40
UniQure NV, Subsidiaries 41

List of Figures
UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[UniQure NV (QURE)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • 3-V Biosciences Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary 3-V Biosciences Inc (3-V Biosciences) is a clinical-stage pharmaceutical company that develops novel therapeutics in metabolic diseases. The company offers TVB-2640, a fatty acid synthase inhibitor used for the treatment of solid tumors, including non-small cell lung cancer (NSCLC), breast c …
  • Providence Resources plc (PZQA)：企業の財務・戦略的SWOT分析
    Summary Providence Resources Plc (Providence Resource) is an upstream oil and gas exploration and development company that explores and develops hydrocarbon assets. The company's areas of operations include Northern Porcupine basin, Southern Porcupine basin, Goban Spur basin, Saint George's basin an …
  • Biglari Holdings Inc.：企業の戦略・SWOT・財務情報
    Biglari Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Biglari Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hornbeck Offshore Services Inc (HOS)：企業の財務・戦略的SWOT分析
    Hornbeck Offshore Services Inc (HOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Expeditors International of Washington, Inc.：企業の戦略・SWOT・財務情報
    Expeditors International of Washington, Inc. - Strategy, SWOT and Corporate Finance Report Summary Expeditors International of Washington, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Unicharm Corporation (8113)：企業の財務・戦略的SWOT分析
    Unicharm Corporation (8113) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Consort Medical plc (CSRT)：医療機器：M&Aディール及び事業提携情報
    Summary Consort Medical plc (Consort Medical) is a contract development and manufacturing organization (CDMO) with focus on medical device technologies for drug delivery. It develops, manufactures and markets high volume disposable medical devices for drug delivery and point-of-care (POC) diagnostic …
  • Laboratoires Pierre Fabre SA-製薬・医療分野：企業M&A・提携分析
    Summary Laboratoires Pierre Fabre SA (Pierre Fabre), a subsidiary of Pierre Fabre Foundation develops products and solutions ranging from health to beauty. Its product portfolio comprises wide range of complementary products, from prescribed drugs to dermo-cosmetics, including over-the-counter drugs …
  • Sirona Biochem Corp (SBM)：企業の財務・戦略的SWOT分析
    Summary Sirona Biochem Corp (Sirona Biochem) is a biotechnology company that discovers and develops therapeutics, cosmeceuticals and biological ingredients. The company develops drugs for diabetes and cancer. It provides cosmeceutical programs such as development of anti-aging and depigmenting agent …
  • E.ON SE (EOAN)-エネルギー分野：企業M&A・提携分析
    Summary E.ON SE (E.ON), formerly E.ON AG, is an energy company that generates electricity, produces, stores, transports, and supplies gas and conducts trading, carbon sourcing, and electricity and gas distribution. It generates power from diverse fuel sources including wind, hydro, nuclear, coal, na …
  • Storz Medical AG：企業の戦略的SWOT分析
    Storz Medical AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Addison Lee Group：企業の戦略的SWOT分析
    Addison Lee Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Delta Electronics (Thailand) Public Company Ltd. (DELTA)：企業の財務・戦略的SWOT分析
    Delta Electronics (Thailand) Public Company Ltd. (DELTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company …
  • Belize Electricity Ltd：企業の戦略的SWOT分析
    Belize Electricity Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Senhwa Biosciences Inc (6492)-製薬・医療分野：企業M&A・提携分析
    Summary Senhwa Biosciences Inc (Senhwa) is a drug development company that develops small molecule drugs for the treatment of cancer. The company’s products include CX-5461 and CX-4945. Its CX-5461 is a p53 activating Pol I inhibitor and anticancer compound for treating hematological malignancies. S …
  • University Health Network-製薬・医療分野：企業M&A・提携分析
    Summary University Health Network (UHN) is a health care institution that provides patient care, research and educational services, and patient support services. It offers health care services such as palliative care, pharmacy and telehealth. UHN also provides specialized program services, accessibi …
  • Edmond De Rothschild (Suisse) S.A.
    Edmond De Rothschild (Suisse) S.A. - Strategy, SWOT and Corporate Finance Report Summary Edmond De Rothschild (Suisse) S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • XuanZhu Pharma Co Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary XuanZhu Pharma Co Ltd (XuanZhu), a subsidiary of Sihuan Pharmaceutical Holdings Group Ltd, is a developer and manufacturer of medicinal products. The company’s products comprise anti-infective drugs apapenem and benapenem; anti-acid drug anaprazole sodium, anti-diabetic drug imigliptin hydro …
  • CTI BioPharma Corp (CTIC)-製薬・医療分野：企業M&A・提携分析
    Summary CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company’s lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or r …
  • Avacta Group Plc (AVCT)：企業の財務・戦略的SWOT分析
    Summary Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products that include optim and sensipod. It also develops UCB celltech that is an analytical instrument. Avacta’s sensipod is an …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆